EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Storage and Stability of AAV-Containing Fibrin Hydrogels for Retinal Gene Therapy

Aubrey Berger iD, Travis Knudsen, Francesca Kopp, David Korda iD, Mary Lang iD, Brittni A Scruggs, Alan D Marmorstein iD

Gels · 02.07.2026 · 12 (7) · 591

DOI: 10.3390/gels12070591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gels, online erschienen am 02.07.2026. Verfasst von Aubrey Berger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Graduate Program, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mayo Clinic, Goldman Philanthropic Partnerships.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subretinal and intravitreal injection of retinal gene therapy is associated with serious adverse events and poor efficacy. We sought to improve retinal gene therapy delivery by developing fibrin hydrogel encapsulated adeno-associated virus (FE-AAV). Here we investigate conditions for storage and stability for FE-AAV. FE-AAV containing 1.9 × 109 genome copies of AAV2/2-CMV-GFP was manufactured using fibrinogen reconstituted in 0.01 M sodium citrate, pH 7 (NaC) or phosphate-buffered saline containing 0.001% (v/v) Pluronic F68 (F68). Samples were stored at either −80 °C or 4 °C for up to 16 weeks. Changes in transduction efficiency, and mechanical and physical properties were evaluated. In vitro transduction was significantly (p < 0.05) reduced for FE-AAV manufactured with NaC. In contrast, we observed no change in transduction through 16 weeks for FE-AAV made with F68. Physical changes occurred in FE-AAV stored at −80 °C. In contrast to FE-AAV formulated with NaC, FE-AAV formulated with F68 and stored at 4 °C for 16 weeks was essentially equivalent to freshly made FE-AAV and retained the ability to transduce retinal pigment epithelial (RPE) cells in the pig eye. We conclude that FE-AAV formulated with F68 and stored at 4 °C is stable and shows potential for retinal gene therapy for at least 4 months following manufacture.

Schlagwörter

Stichwörter der Autor:innen

AAVgene therapyhydrogelretinal diseasestabilitystorage

Autor:innen und Institutionen

  • Biomedical Graduate Program, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, USA.
  • Mayo Clinic Alix School of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Department of Pediatrics, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Aubrey Berger, David Korda, Mary Lang, Alan D Marmorstein

Förderung

  • Mayo Clinic
  • Goldman Philanthropic Partnerships

Zitieren

APA

Berger, A., Knudsen, T., Kopp, F., Korda, D., Lang, M., Scruggs, B. A., & Marmorstein, A. D. (2026). Storage and Stability of AAV-Containing Fibrin Hydrogels for Retinal Gene Therapy. Gels, 12(7), 591. https://doi.org/10.3390/gels12070591

Vancouver

Berger A, Knudsen T, Kopp F, Korda D, Lang M, Scruggs BA, et al. Storage and Stability of AAV-Containing Fibrin Hydrogels for Retinal Gene Therapy. Gels. 2026;12(7):591. doi:10.3390/gels12070591

BibTeX
@article{Berger2026,
  author = {Berger, Aubrey and Knudsen, Travis and Kopp, Francesca and Korda, David and Lang, Mary and Scruggs, Brittni A and Marmorstein, Alan D},
  title = {Storage and Stability of AAV-Containing Fibrin Hydrogels for Retinal Gene Therapy},
  journal = {Gels},
  year = {2026},
  volume = {12},
  number = {7},
  pages = {591},
  doi = {10.3390/gels12070591}
}
Kostenlos starten →